Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.

Diego F Wyszynski Lydia Demetriou Cheryl Renz Shirin Aliabadi Dragutin Rafailovic Lee P Shulman Myriam Drysdale Keele E Wurst

Published in: Drug safety (2024)

A sizable proportion of sotrovimab-treated participants in the COVID-PR had underlying medical conditions associated with an increased risk of severe COVID-19. None of the assessable SAEs were considered to be related to sotrovimab treatment.

Keyphrases

coronavirus disease
sars cov
preterm birth
healthcare
respiratory syndrome coronavirus
mental health
emergency department
drug induced